Live Webinar: 2 March 2022, 4 pm CET
Organised by ECTS
Sponsored by Industry
Date & Time: 2 March 2022, 4 pm CET
Featuring Stuart Ralston, Chaired by Gavin Clunie & Ciro Menale
Costs: Live & On-demand webinar is free for ECTS members and non-members, but a registration is required.
- 5 min introduction
- 25 min meet-the-expert presentation
- 30 min Q&A and Case Discussion
- To be aware of the various conditions that can present with osteosclerosis
- To be aware of the clinical features and investigations that can help differentiate between different osteosclerotic disorders
- To be aware of the treatment options for individual osteosclerotic disorders
The ECTS Rare Bone Diseases Webinar – Sorting out Sclerosing Bone Dysplasias, 2 March, has been submitted for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME®) for European CME credits (ECMEC®s).
Featuring Prof. Dr. José A. Riancho
José A. Riancho is Professor of Medicine at the University of Cantabria, as well as Chief of Section of Internal Medicine at the University Hospital M. Valdecilla, both in Santander, Spain. He has extensive clinical experience in the management of patients with osteoporosis and other metabolic bone disorders. His research is focused on the genomics and epigenomics of osteoporosis and other skeletal disorders. He has published more than 200 papers in international peer-reviewed journals, including several studies about the clinical and genetic characteristics of adult patients with hypophosphatasia. He is a member of the the Spanish Society for Research on Osteoporosis and Mineral Metabolism (SEIOMM), The European Society of Calcified Tissues, and the American Society for Bone and Mineral Research. He also participates in several international consortia investigating the genetic basis of skeletal disorders.
Moderated by Dr Thomas Funck-Brentano
Breast cancer cells frequently disseminate to the bone marrow, where they may either enter a dormant state or colonize the bone and induce osteolysis. The mechanisms that regulate tumor cell entry and exit from dormancy in the bone are not well understood, but several factors have been identified. Previous work from our group found that leukemia inhibitory factor receptor (LIFR) promotes tumor dormancy when expressed on bone-disseminated tumor cells and that loss of LIFR enables otherwise dormant tumor cells to colonize the bone. Our lab has therefore examined how LIFR expression is regulated in breast cancer cells, with the hope that understanding its regulation might provide novel avenues to therapeutically target dormant disseminated tumor cells. Through these efforts we have found that LIFR is epigenetically regulated, and that histone deacetylase (HDAC) inhibitors, which are FDA-approved for several blood cancers, stimulate LIFR expression on breast cancer cells from all subtypes. This finding presents an interesting therapeutic opportunity to explore whether HDAC inhibitors may be used to promote a chronic state of tumor dormancy and prevent recurrence in bone. Our findings suggest that this may be feasible, but that the effects of histone deacetylase inhibitors on bone remodeling profoundly impact tumor colonization and must be combined with appropriate anti-resorptive therapies.